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Abstract
Dysfunction of renin-angiotensin system (RAS) contributes to the pathogenesis of diabetic retinopathy (DR). Prorenin, the
precursor of renin is highly elevated in ocular fluid of diabetic patients with proliferative retinopathy. Prorenin may exert
local effects in the eye by binding to the so-called (pro)renin receptor ((P)RR). Here we investigated the combined effects of
the renin inhibitor aliskiren and the putative (P)RR blocker handle-region peptide (HRP) on diabetic retinopathy in
streptozotocin (STZ)-induced diabetic transgenic (mRen2)27 rats (a model with high plasma prorenin levels) as well as
prorenin stimulated cytokine expression in cultured Mu¨ller cells. Adult (mRen2)27 rats were randomly divided into the
following groups: (1) non-diabetic; (2) diabetic treated with vehicle; (3) diabetic treated with aliskiren (10 mg/kg per day);
and (4) diabetic treated with aliskiren+HRP (1 mg/kg per day). Age-matched non-diabetic wildtype Sprague-Dawley rats
were used as control. Drugs were administered by osmotic minipumps for three weeks. Transgenic (mRen2)27 rat retinas
showed increased apoptotic cell death of both inner retinal neurons and photoreceptors, increased loss of capillaries, as
well as increased expression of inflammatory cytokines. These pathological changes were further exacerbated by diabetes.
Aliskiren treatment of diabetic (mRen2)27 rats prevented retinal gliosis, and reduced retinal apoptotic cell death, acellular
capillaries and the expression of inflammatory cytokines. HRP on top of aliskiren did not provide additional protection. In
cultured Mu¨ller cells, prorenin significantly increased the expression levels of IL-1a and TNF-a, and this was completely
blocked by aliskiren or HRP, their combination, (P)RR siRNA and the AT1R blocker losartan, suggesting that these effects
entirely depended on Ang II generation by (P)RR-bound prorenin. In conclusion, the lack of effect of HRP on top of aliskiren,
and the Ang II-dependency of the ocular effects of prorenin in vitro, argue against the combined application of (P)RR
blockade and renin inhibition in diabetic retinopathy.
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Introduction
Diabetic retinopathy (DR) is the most common diabetic
microvascular complication and the leading cause of severe vision
loss in people under the age of sixty [1]. The prevalence of DR
increases with the duration of diabetes, and nearly all individuals
with type 1 diabetes and more than 60% of those with type 2
diabetes have some form of retinopathy after 20 years [2,3].
Several molecular, biochemical and hemodynamic pathways
have been identified to contribute to the pathogenesis of DR [4].
Hyperactivity of the renin-angiotensin system (RAS), resulting in
elevated concentrations of its principal effector peptide, angioten-
sin (Ang) II, plays a key role in activating pathways leading to
increased vascular inflammation, oxidative stress, endothelial
dysfunction and tissue remodeling in variety of conditions,
including diabetes and its associated complications [5,6]. As a
result, RAS inhibitors are first-line therapeutic agents for treating
patients with cardiovascular diseases, cardiometabolic syndrome
and diabetes. Although the RAS was classically considered a
circulating system having general systemic effects, it is now
recognized that there are also local tissue RASs, for instance in the
retina [7]. Activation of such local RASs may contribute to end-
organ damage in diabetes and associated complications [7,8].
It has long been recognized that diabetes with microvascular
complications is associated with increased plasma prorenin [9,10].
Relative to albumin, ocular fluids contain higher concentrations of
prorenin than plasma, and ocular prorenin increases even further
in diabetic patients with proliferative retinopathy [10–12]. This
has led to the suggestion that prorenin may be a marker of diabetic
complications [10]. Elevated prorenin may contribute to diabetic
complications by binding to its putative receptor, the so-called
(pro)renin receptor ((P)RR). Such binding activates prorenin,
leading to increased angiotensin generation in target tissue and
subsequent signaling by the classic RAS pathway [13]. In addition,
binding of (pro)renin to the (P)RR also directly initiates a cascade
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of signaling events involving mitogen-activated protein kinases
such as ERK1/2 and p38, that are known to be associated with
profibrotic and proliferative actions independent of Ang II [13,14].
The role of (P)RR in end-organ damage and diabetic complica-
tions is supported by several studies demonstrating that an
inhibitor of (P)RR, a peptide derived from the prosegment of
prorenin, the so-called handle-region peptide (HRP), afforded
renal and cardiovascular protection [15,16], presumably by
inhibiting the binding of prorenin to the (P)RR [17]. HRP has
also been shown to be beneficial in ocular pathologies [18–21].
Aliskiren is the first renin inhibitor that blocks the activity of
renin, a key rate-limiting enzyme in the first step of the RAS
cascade [22]. It has shown high efficacy not only in controlling
blood pressure [23], but also in renal and cardiovascular
protection [24,25]. It is also effective in patients with metabolic
syndrome, obesity and diabetes [26,27], as well as in experimental
atherosclerosis [28,29]. Although aliskiren is able to bind to (P)RR-
bound renin and prorenin [30–32], its role in (P)RR-mediated
Ang II-independent signaling remains controversial with conflict-
ing reports [33,34]. We have previously shown that HRP
unexpectedly counteracted some of the beneficial effects of
aliskiren [35,36]. In the present study, we investigated the effects
of aliskiren on diabetes-induced retinopathy in a transgenic rat
model overexpressing the mouse renin gene, i.e., the (mRen2)27
rat (Ren2 rat). This rat exhibits significantly elevated prorenin and
Ang II levels, and displays increased PRR expression and severe
hypertension [37–40]. After streptozotocin injection, these animals
develop a diabetic phenotype that closely mimics that in diabetic
patients, characterized by high prorenin levels, retinal pathology,
vascular dysfunction and nephropathy [41,42]. We also examined
the effects of HRP on top of renin inhibition with aliskiren. Our
data show that renin inhibition with aliskiren reduced both
neuronal and vascular pathologies in the diabetic Ren2 rat retina,
and that HRP on top of aliskiren did not provide additional
protection, nor counteracted the beneficial effects of aliskiren.
Materials and Methods
Animals and treatment groups
Adult heterozygous Ren2 rats (400–500 g) with a Sprague–
Dawley (SD) background [36] were used in this study. Rats were
housed in individual cages and maintained on a 12-h light/dark
cycle, having access to standard laboratory rat chow and water ad
libitum. All procedures were performed under the regulation and
approval of the Animal Care Committee of the Erasmus MC.
Blood pressure was measured by radiotelemetry transmitters that
were implanted as described before [43] two weeks prior to
diabetes induction. To induce diabetes, rats were fasted overnight
and administered streptozotocin (STZ; 55 mg/kg i.p., Sigma–
Aldrich, Zwijndrecht, The Netherlands). Blood glucose levels were
checked by tail incision (Precision Xceed, Abbott, Zwolle, The
Netherlands). Only rats with a glucose level .15 mmol/L were
considered diabetic, and they subsequently received 2–4 U insulin
per day (Levemir, Novo Nordisk, Denmark). Aliskiren (a gift of
Novartis, 10 mg/kg per day) with (n = 8) or without (n = 7) rat
HRP (NH2- RILLKKMPSV-COOH, 1 mg/kg per day, Bio-
synthan, Berlin, Germany), or vehicle (saline, n= 8) were
administered for 3 weeks by osmotic minipumps (2ML4 ALZET,
Cupertino, USA) implanted subcutaneously two weeks after
diabetes induction. In the animals receiving two drugs, two
separate minipumps were implanted at both sides of the body.
Eyes were collected at the end of the treatment period. For
comparison, eyes were also collected from 9 untreated nondiabetic
Ren2 rats, and 5 age-matched untreated SD rats.
Retinal histology and immunofluorescence
Eyes were fixed in 4% paraformaldehyde freshly made in
phosphate-buffered saline (PBS) at 4uC overnight. Eyecups were
cryoprotected in 30% sucrose/PBS for several hours or overnight
prior to quick freezing in optical cutting temperature (OCT)
compound. Then 12 mm thick sections were cut at –20 to –22uC.
A rabbit polyclonal antibody against glial fibrillary acidic protein
(GFAP, 1:1000, Sigma, St. Louis, MO), was used. The secondary
antibody (conjugated with Alexa594) was from Molecular Probes
(Invitrogen, Carlsbad, CA) and used according to the manufac-
turer’s instruction. Sections were coverslipped using VECTA-
SHIELD (Vector Laboratories, Burlingame, CA), and examined
with a Zeiss (AxionVision, Carl Zeiss MicroImaging, Inc, NY)
microscope equipped with epifluorescence illumination and a high
resolution digital camera. For morphological analysis, eyes were
fixed in 10% formalin solution, processed for paraffin embedding,
sectioned at a thickness of 4 mm, and stained with hematoxylin
and eosin (H&E). For quantitative measurement of retinal
ganglion cell (RGC) density, the number of nuclei in the RGC
layer was counted from at least 10 sections from each eye, 4 eyes
from each group.
In situ cell death detection
To detect apoptotic cells, an In Situ Cell Death Detection Kit
based on TUNEL technology (In Situ Cell Death Detection Kit,
TMR red, Roche Applied Science, Indianapolis, IN, USA) was
used according to the instructions supplied by the manufacturer.
Retinal vascular preparation and H&E staining
Retinal vasculature was prepared using method as described
previously [44]. Briefly, eyes were fixed in 4% paraformaldehyde
freshly made in PBS overnight. Retinas were dissected out from
the eyecups and digested in 3% trypsin (GIBCO-BRL) for 2–3
hours at 37uC. Retinal vessels were separated from other retinal
neuronal cells by gentle shaking and manipulation under a
dissection microscope. The vessels were then mounted on a clean
slide, allowed to dry, and stained with PAS-H&E (Periodic Acid
Solution- Hematoxylin, Gill No.3, Sigma, St. Louis, MO)
according to the instruction manual. After staining and washing
in water, the tissue was dehydrated and mounted in permount
mounting media. The prepared retinal vessels were photographed
using a Zeiss microscope equipped with a high resolution digital
camera (AxioCam MRC5, Zeiss Axionvert 200). Six to eight
representative, non-overlapping fields from each quadrant of the
retina were imaged. Acellular capillaries were counted from
images for each retina, and expressed as number of acellular
vessels per mm2.
RT-PCR of inflammatory cytokines
Total RNA was isolated from freshly dissected retinas using
Trizol Reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instruction. Reverse transcription was performed
using Enhanced Avian HS RT-PCR kit (Sigma, St. Louis, MO)
following the manufacturer’s instructions. Real time PCR was
carried out on a real time thermal cycler (iCycler, Bio-Rad Life
Sciences) using iQTM Syber Green Supermix (Bio-Rad Life
Sciences). The threshold cycle number (Ct) for real-time PCR was
set by the cycler software. Optimal primer concentration for PCR
was determined separately for each primer pair. The primer
sequences used in this study are shown in Table 1. Each reaction
was run in duplicate or in triplicate, and reaction tubes with target
primers and those with GAPDH/actin primers were always
included in the same PCR run. To test the primer efficiencies, the
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one-step RT-PCR was run with each target primer. Relative
quantification was achieved by the comparative 2-DDCt method1.
The relative increase/decrease (fold-induction/repression) of
mRNA of target X in the experimental group (EG) was calculated
using the control group as the calibrator: 2-DDCt, where DD Ct is
{Ct.x [EG] -Ct. GAPDH [EG]} - {Ct.x [control] - Ct. GAPDH
[control]}.
Cell culture and treatment
Mu¨ller cells (a kind gift of Dr. G. Astrid Limb, UCL Institute of
Ophthalmology, London, United Kingdom) [45] were cultured in
24-well plates with Dulbecco’s Modified Eagle Medium (DMEM)
(Thermo Fisher Scientific, Waltham, MA) containing 10% fetal
bovine serum (FBS) (Thermo Fisher Scientific, Waltham, MA).
The ON-Target plus (P)RR siRNA and scrambled control siRNA
were from (Thermo Fisher Scientific, Waltham, MA). Different
concentrations and incubation times of (P)RR-siRNA were pre-
tested to determine the optimal concentration and incubation time
according to the manufacturer’s recommendation. Cells grown to
70% confluence in the serum medium were replaced by Opti-
MEM I-reduced serum medium (Life Technologies, Carlsbad,
CA), and the ON-Target plus (P)RR siRNA or control siRNA, or
vehicle only was added into the medium at a final concentration of
30 nmol/L. After 24-hour incubation with the siRNA, the cells
were replaced with serum-free DMEM medium (Thermo Fisher
Scientific, Waltham, MA) for 2 hours. Following the serum
starvation, the cells were either untreated (control) or treated with
prorenin (100 nmol/L) alone, prorenin (100 nmol/L) + HRP
(10 mmol/L, GenScript), prorenin + aliskiren (10 mmol/L), prore-
nin + HRP (10 mmol/L) + aliskiren (10 mmol/L), and prorenin
(100 nmol/L) + losartan (10 mmol/L, according to previous
studies [46]). After the 6 hour incubation, cells were harvested
and total RNA was extracted, real time RT-PCR was performed
and analyzed using the methods described previously.
Statistics
All values are presented as mean 6 SD. Paired Student’s t-test
was used to assess significance between two groups. One-way
ANOVA followed by the post hoc Tukey (Fisher’s protected least
significant difference) test was used to assess statistical significance
between multiple groups. Differences were considered significant
at p,0.05.
Results
Induction of diabetes mellitus and blood pressure
Blood glucose levels and mean arterial pressure (MAP) have
been reported before [36]. In short, Ren2 rats had a normal blood
glucose level, identical to that in Sprague–Dawley (SD) rats. STZ-
induced diabetes mellitus increased blood glucose levels ,5-fold,
and treatment with aliskiren or aliskiren+HRP did not alter this.
Aliskiren lowered MAP in Ren2 rats from 12364 mmHg to
10465 mm Hg, and this effect was unaltered by simultaneous
administration of HRP [47].
Retinal gliosis
Retinal gliosis, a salient feature of the retina under stress or
injury including diabetic retinopathy, is characterized by elevated
expression of the intermediate filament, glial fibrillary acidic
protein (GFAP) in Mu¨ller cells and astrocytes. GFAP is normally
predominantly expressed in astrocytes in the inner retinal fiber
layer (Figure 1a, b). A slight increase of GFAP expression was
observed in astrocytes of the retina of non-diabetic Ren2 rats, but
this was not different from the wildtype SD rat retina (Figure 1c,
d). GFAP expression was elevated in the diabetic Ren2 rat retina
(Figure 1e, f), and aliskiren prevented this elevation, both without
(Figure 1g, h) and with HRP (Figure 1i, j).
Apoptosis and RGC loss
In the SD rat retina, very few apoptotic cells could be detected
(data not shown). The Ren2 rat retina showed a significant
increase of TUNEL positive apoptotic cells in both inner retina
Table 1. Primers used for Real-Time RT-PCR analysis.
Gene name Accession # Sequences
Rat VEGF NM_031836 Forward: 59 -TGCACCCACGACAGAAGGGGA-39
Reverse: 59-TCACCGCCTTGGCTTGTCACAT-39
Rat MCP1 NM_031530 Forward: 59 -GCAGCAGGTGTCCCAAAGAAGCT-39
Reverse: 59-AGAAGTGCTTGAGGTGGTTGTGGAA-39
Rat ICAM1 NM_012967 Forward: 59 -CCCCACCTACATACATTCCTAC-39
Reverse: 59-ACATTTTCTCCCAGGCATTC-39
Rat TNFa NM_012675 Forward: 59 -CCTTATCTACTCCCAGGTTCTC-39
Reverse: 59-TTTCTCCTGGTATGAAATGGC-39
Rat GAPDH AF106860 Forward: 59 -TGCTGGGGCTGGCATTGCTC-39
Reverse: 59- CCCCAGGCCCCTCCTGTTGT-39
Human IL-1a NM_000575 Forward: 59-ATCAGTACCTCACGGCTGCT-39
Reverse: 59-TGGGTATCTCAGGCATCTCC-39
Human TNFa NM_000594 Forward: 59-ATCTACTCCCAGGTCCTCTTCAA-39
Reverse: 59-GCAATGATCCCAAAGTAGACCT-39
Human b actin NM_001101 Forward: 59-GCAGGAGTATGACGAGTCCG-39
Reverse: 59-AGGGACTTCCTGTAACAATGC-39
doi:10.1371/journal.pone.0100954.t001
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and photoreceptor layer (Figure 2a, b), and this increase was more
prominent in the peripheral retina (Figure 2b) compared with the
central retina (Figure 2a). This increase in apoptotic cells was
dramatically further exacerbated in the diabetic Ren2 rat retina
(Figure 2c, d). Treatment with either aliskiren alone or aliskiren+
HRP significantly reduced apoptotic cell death to levels in the SD
rat retina (Figure 2e, f, g). Morphologically the central retina of
non-diabetic Ren2 rat is indistinguishable from wild type rat
retina, however there is significant cell loss in the retinal ganglion
cell (RGC) layer in peripheral retina (Figure 3). The diabetic Ren2
rat retina showed significantly increased cell loss in the RGC layer,
which was more profound in the peripheral retina. The cell loss
was normalized by either aliskiren or aliskiren+HRP treatment
(Figure 3).
Retinal capillaries
The Ren2 rat retina showed an increased loss of capillaries
compared to age-matched SD rat retinas (Figure 4A and B), and
this loss was further exacerbated in diabetic Ren2 rat retinas
(Figure 4C). Aliskiren reduced the acellular capillaries to the level
seen in non-diabetic Ren2 rat retina (Figure 4D), but the number
of acellular capillaries was still significantly higher compared to
that of the SD retina. HRP treatment in combination with
aliskiren did not add additional protection against capillary loss
(Figure 4E). Figure 4F displays these results in a quantitative
manner.
Retinal inflammatory cytokines
Inflammatory cytokine expression in the retina was evaluated by
real-time RT-PCT. VEGF expression was increased .2-fold in
the Ren2 rat retina compared to age-matched SD rat retinas, and
this increase was even larger in diabetic Ren2 rat retinas.
Treatment with either aliskiren alone or combined with HRP
reduced VEGF to non-diabetic Ren2 rat levels (Figure 5). MCP-1
expression was also significantly increased in Ren2 rat retinas with
or without diabetes mellitus and aliskiren alone or in combination
with HRP normalized this (Figure 5). A significant increase of
ICAM1 was only seen in diabetic Ren2 rat retinas, and both
aliskiren and aliskiren+HRP normalized this (Figure 5). TNFa
expression was also highly increased in the Ren2 rat retina, and
diabetes mellitus further upregulated this. Aliskiren significantly
reduced TNFa to non-diabetic Ren2 rat levels. Aliskiren+HRP
tended to reduce this even further, but the difference versus
aliskiren was not statistically significant.
Increased cytokine expression stimulated by
recombinant prorenin in cultured human Mu¨ller glial
cells and blockade by HRP and aliskiren
Mu¨ller cells, which span the entire neural retina, are the
primary glial cell of the retina. They not only provide architectural
support of the neural layers, but also have multiple functions such
as providing metabolic support to energy-demanding retinal
neurons, regulation of retinal synaptic activity by neurotransmitter
recycling, and regulation of retinal water and ion homeostasis
[48,49]. Mu¨ller cells are intimately connected with retinal
endothelial cells, pericytes, and astrocytes and play a crucial role
to establish and maintain the blood–retinal barrier (BRB) [48,49].
In addition, Mu¨ller cells modulate retinal immunity [50].
Moreover, Mu¨ller cells express several RAS components [7,51],
including (pro)renin [52] and its receptor (P)RR, so that Mu¨ller
cell dysfunction might contribute to ocular dysregulation in
diabetes [18,21,53,54]. In fact, ocular prorenin upregulation is
known to occur in patients with proliferative [10–12]. Prorenin
was previously shown to increase proinflammatory cytokine
expression in cultured neurons [55], To determine whether
prorenin is also able to increase the expression of proinflammatory
cytokines in Mu¨ller cells, cultured Mu¨ller cells were treated with
prorenin, with and without HRP, aliskiren and/or the AT1R
blocker losartan. The expression levels of IL-1a and TNF-a at 6
hours after the prorenin treatment were examined. Our results
showed that the prorenin treatment significantly increased the
expression of IL-1a (by ,12-fold) TNF-a (by ,3-fold) (Figure 6).
Both aliskiren and HRP when given separately completely blocked
these increases, and the results were identical when given in
combination. Losartan treatment also completely blocked prore-
nin stimulated increased expression of IL-1a and TNF-a (Figure 6),
suggesting that the increased expression of these cytokines is Ang
II- dependent. (P)RR-siRNA completely blocked the prorenin
stimulated increase of these cytokines, whereas the control
scrambled siRNA had no effect (Figure 6), suggesting that the
prorenin stimulated, Ang II-dependent increase in cytokine
expression in Mu¨ller cells involves (P)RR binding.
Discussion
The present study demonstrates that the Ren2 rat retina
exhibited increased capillary loss and inflammatory cytokine
expressions, and neuronal apoptotic cells. Diabetes mellitus further
exacerbated these changes and enhanced gliosis. Renin inhibition
counterbalanced these phenomena, whereas (P)RR blockade on
top of renin inhibition did not offer additional advantages. The
protective effect of aliskiren on retinal vasculopathy and inflam-
mation in diabetic Ren2 rats is consistent with a previous report
[56]. Diabetic retinopathy is not only associated with vascular
dysfunction, but also with a loss of retinal neurons [57]. Our study
further showed that aliskiren treatment normalized both photo-
receptor and RGC loss in Ren2 rats to wildtype (SD rat) level.
Elevated plasma prorenin levels associate with microvascular
complications in patients with diabetes mellitus. Prorenin is also
highly elevated in ocular fluid in patients with diabetic retinopathy
and its level correlates with the severity of DR in diabetic patients
[10,11]. Prorenin may contribute to diabetic complication and
end-organ damage by binding to the (P)RR, resulting in increased
generation of Ang II by the classic RAS pathway at the cell/tissue
level [13]. Alternatively, such binding may initiate a cascade of
signaling events that are associated with profibrotic and prolifer-
ative actions, independent of Ang II [13]. To what degree
prorenin-(P)RR interaction is physiologically relevant, given the
nanomolar prorenin levels (i.e., several orders above its normal
plasma levels) that are required for such interaction, is still a matter
of debate [58]. Nevertheless, since the eye is a prorenin-producing
organ, with Mu¨ller cells releasing prorenin in the retina [52], if
anywhere, such interaction might occur at ocular sites.
The importance of the (P)RR in the pathogenesis of end-stage
organ damage in diabetes and hypertension has been demonstrat-
ed by in vitro and in vivo animal studies using HRP, the only
(P)RR blocker that is currently available [15]. The possible
Figure 1. Immunofluorescence detection of GFAP expression in the retinas of wildtype (WT) Sprague–Dawley rats, non-diabetic
(NDM) Ren2, diabetic (DM) Ren2 rats treated with vehicle, aliskiren or aliskiren+HRP. ONL: outer nuclear layer; OPL: outer plexiform layer;
INL: inner nuclear layer; IPL: inner plexiform layer; RGC: retinal ganglion cell layer.
doi:10.1371/journal.pone.0100954.g001
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pathological role of the PRR in the retina has been established by
several reports in which HRP was shown to prevent pathological
angiogenesis [18,21], and ocular inflammation induced by
endotoxin [20] and diabetes [19]. It was thus expected that
blockade of both the Ang II-dependent pathway (by aliskiren) and
the (P)RR-mediated, Ang II-independent pathway (by HRP)
would provide better protection against diabetes-induced retinal
pathophysiology. However, the present study showed that HPR
Figure 2. In situ cell death detection in the retina. A, Apoptotic cells were detected in situ by TUNEL assay in the retinas from non-diabetic
(NDM) Ren2 rats (a & b), diabetic (DM) Ren2 rats treated with vehicle (c & d), and aliskiren (e & f). ONL: outer nuclear layer; INL: inner nuclear layer;
RGC: retinal ganglion cell layer. B, Quantitative measurement of apoptotic cells detected by TUNEL assay. #p,0.01 (vs. wildtype (WT) Sprague–
Dawley rats); $p,0.01 (vs. NDM Ren2 and WT); *p,0.01 (vs. NDM Ren2 and DM Ren2+ vehicle).
doi:10.1371/journal.pone.0100954.g002
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Figure 3. Representative retinal micrographs of wildtype (WT) Sprague–Dawley rats, non-diabetic (NDM) Ren2 rats, and diabetic
(DM) Ren2 rats treated with vehicle, aliskiren or aliskiren+HRP (A). INL: inner nuclear layer; IPL: inner plexiform layer; RGC: retinal ganglion
cell layer. Quantitative measurement of cell density in RGC layer in the central (B) and peripheral (C) retinas of wildtype (WT) Sprague–Dawley rats,
non-diabetic (NDM) Ren2 rats, and diabetic (DM) Ren2 rats treated with vehicle, aliskiren or aliskiren+HRP. N= 4. *p,0.01 (vs. WT).
doi:10.1371/journal.pone.0100954.g003
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did not provide additional beneficial effects on top of aliskiren. In
part, this is due to the fact that, with regard to at least some
parameters, aliskiren already provided maximal benefit. This
would suggest that prorenin-dependent effects, if present, might be
largely due to activation of the Ang II-AT1 receptor axis.
Obviously, aliskiren will block angiotensin generation by recep-
tor-bound prorenin (or renin) [31,32]. In addition, renin inhibition
may lower (P)RR expression [33], thus potentially diminishing the
capacity of HRP to exert an effect at all. It is unlikely that aliskiren
blocked renin/prorenin-(P)RR interaction, since renin/prorenin
binding to the (P)RR was unaltered in the presence of aliskiren,
while aliskiren also did not affect (pro)renin-induced signaling
[58,59].
We previously reported that aliskiren normalized vascular
dysfunction in diabetic hypertensive rats, while HRP unexpectedly
counteracted these beneficial vascular effects in a blood pressure-
and angiotensin-independent manner [35,36]. This may be
explained on the basis of partial agonism of HRP towards the
(P)RR [21,60]. Intriguingly, although HRP did not exert beneficial
effects on top of aliskiren in the diabetic Ren2 rat retina, it also did
not counteract the protective ocular effects of aliskiren. Thus,
possibly the retinal levels of HRP (when administered systemically)
were not sufficiently high to generate similar counteracting effects.
Yet, when infused at similar doses alone, HRP did exert beneficial
effects in the diabetic eye [21]. It cannot be excluded that such
effects are (P)RR-independent, but if so, they can apparently no
longer be seen on top of RAS blockade.
Hypertension plays an important role in retinal pathophysiology
and is one of the major risk factors that exacerbates the initiation
and progression of DR [1]. As shown in our previous report [36],
diabetic Ren2 rats displayed severely elevated blood pressure;
aliskiren normalized blood pressure, suppressed renin activity, and
Figure 4. Representative capillary images of wildtype (WT) Sprague–Dawley rats (A), non-diabetic (NDM) Ren2 rats (B), and diabetic
(DM) Ren2 rats treated with vehicle (C), aliskiren (D) or aliskiren+HRP (E). Diabetic Ren2 rat retinas showed further increased acellular
capillaries (arrow) and both aliskiren and aliskiren+HRP reduced this. F: Quantitative measurements of acellular capillaries. *P,0.01 (vs. DM Ren2+
vehicle group).
doi:10.1371/journal.pone.0100954.g004
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reversed vascular dysfunction, whereas HRP did not affect the
blood pressure-lowering effects of aliskiren [15,35,61]. The
beneficial effects of aliskiren in the diabetic Ren2 rat retina may
be due to its blood pressure-lowering effect and associated
improvement of renal and other systemic cardiovascular function.
However, in a previous study in the same model, ACE inhibition
resulted in better blood pressure control, while aliskiren provided
greater retinal protection [56]. This strongly suggests that the
beneficial effects of renin inhibition extend beyond the blood
pressure-lowering effects of aliskiren. Clearly, this needs to be
tested in normotensive animal models of diabetic retinopathy in
future studies.
In cultured Mu¨ller cells, prorenin significantly increased the
expression levels of IL-1a and TNF-a, consistent with previous
observations [55]. Both aliskiren and HRP completely blocked
these effects as did treatment with (P)RR siRNA and the AT1R
blocker losartan. This suggests that these prorenin-induced effects
are entirely (P)RR- and Ang II-dependent, i.e., involve Ang II
generation by (P)RR-bound prorenin, identical to the prorenin-
dependent Ang II generation described earlier in vascular smooth
muscle cells [58]. Possibly, such generation also contributes to the
elevated ocular Ang II levels under many pathological conditions
[10–12,51,62–64].
Recent evidence clearly indicates the (P)RR as multi-functional
receptor, affecting a wide range of signaling pathways, many of
which are not necessarily related to prorenin and Ang II/AT1R
signaling. In fact, a truncated form of (P)RR at the C-terminal
region was previously described as a vacuolar H+ -ATPase (V-
Figure 5. Real-time RT-PCR analysis of retinal expression of inflammatory cytokines: VEGF, MCP1, ICAM1 and TNFa. Values on y-axis
represent fold change in mRNA levels compared to WT (normalized as 1). *P,0.01 (vs. DM Ren2+vehicle group). WT, wildtype, DM/NDM, diabetic/
nondiabetic. N = 5.
doi:10.1371/journal.pone.0100954.g005
Figure 6. Real-time RT-PCR analysis of the expression of inflammatory cytokines IL-1a and TNF-a in cultured Mu¨ller cells. Values on y-
axis represent fold change in mRNA levels compared to control (non-treated, normalized as 1). *P,0.01 (vs. control); # P,0.01 (vs. prorenin treated
group). N = 4.
doi:10.1371/journal.pone.0100954.g006
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ATPase) associated protein (Atp6ap2), and the (P)RR may thus
also affect V-ATPase activity [65]. Such activity determines the
intracellular pH homeostasis that is critical in diverse physiological
cellular functions including endocytosis, processing of proteins and
signaling molecules, membrane sorting and trafficking, activation
of lysosomal and autophagosomal enzymes, and patterning during
development [66,67]. Consequently, it is conceivable that the
(P)RR contributes not only to tissue RAS activation but also to
multiple molecular and cellular processes via its V-ATPase
connection. Further studies are required to further elucidate
whether prorenin affects these functions.
In conclusion, the renin inhibitor aliskiren reduced both
neuronal and vascular pathologies, including retinal gliosis,
apoptotic cell death of retinal neurons, acellular capillaries and
expression of inflammatory cytokines in diabetic mRen2 rats. The
putative (P)RR blocker HRP did not provide add-on beneficial
effects when combined with aliskiren, nor counteracted the effects
of aliskiren in the retina of diabetic mRen2 rats. The latter
contrasts with earlier observations in the kidney of diabetic mRen2
rats, where HRP counteracted the beneficial effects of aliskiren
[47]. The former agrees with our in-vitro studies in Mu¨ller cells,
showing prorenin-induced effects that are entirely Ang II-
dependent. Taken together, these results suggest that aliskiren is
a promising treatment option for patients with diabetic retinop-
athy, and that its combination with HRP in this condition is not
advisable.
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